Bank of America Corp DE Trims Holdings in Natera, Inc. (NASDAQ:NTRA)

Bank of America Corp DE decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 519,581 shares of the medical research company’s stock after selling 27,190 shares during the period. Bank of America Corp DE owned about 0.39% of Natera worth $82,250,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Principal Securities Inc. grew its position in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC grew its position in shares of Natera by 1.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares in the last quarter. Silver Oak Securities Incorporated grew its position in shares of Natera by 3.1% during the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares in the last quarter. Blue Trust Inc. grew its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. Finally, Utah Retirement Systems grew its position in shares of Natera by 1.6% during the 4th quarter. Utah Retirement Systems now owns 6,200 shares of the medical research company’s stock worth $981,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $150.99 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $20.41 billion, a PE ratio of -85.79 and a beta of 1.79. The business has a 50-day simple moving average of $147.51 and a two-hundred day simple moving average of $155.90. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter last year, the company earned ($0.56) earnings per share. The company’s quarterly revenue was up 36.5% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NTRA shares. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research report on Friday. Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group increased their price target on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Finally, Morgan Stanley raised their price objective on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $181.82.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 87,272 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the completion of the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,160,963.60. This trade represents a 30.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares of the company’s stock, valued at approximately $1,433,183.76. The trade was a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,436 shares of company stock worth $22,019,079 over the last three months. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.